《新股消息》傳康聖環球基因技術啓動預路演 料籌4億美元
內地獨立臨牀特檢服務提供商康聖環球基因技術已通過上市聆訊,外電消息指,康聖環球正進行預路演活動,以瞭解機構投資者意向,料至下週三結束,預期集資約3億至4億美元。
聆訊後招股資料顯示,該公司以主要業務爲提供臨牀檢驗服務,包括血液學、遺傳病及罕見病、傳染病、腫瘤、神經學、婦科檢測、COVID-19及常規檢測等,服務對象包括醫院、合約研究機構、臨牀試驗贊助商、製藥公司及研究機構。
康聖環球於去年度錄得收入8.91億元人民幣(下同),按年增長7%;期內錄虧損9.74億元,較2019年的虧損1.69億元擴大。
公司於上市前融資引入多名投資者,包括五源資本(前稱晨興資本)旗下HCA Investments、中國銀行(03988.HK)旗下BOCI Financial Products、投資機構Investcorp、CPE、私募股權基金Forebright及農行(01288.HK)旗下農銀國際投資等。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.